465 Studies Now Enrolling
A randomized, Double-Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Acute Kidney Injury in Subjects at High Risk for AKI Following Cardiac Surgery
A study for patients who have had Cardiac surgery using study drug QPI-1002
| Sponsor: | Quark Pharmaceuticals, Inc. |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAQ5716 |
| U.S. Govt. ID: | NCT02610283 |
| Contact: | Christopher Depender: 212-305-3009 / cd2686@columbia.edu |
Additional Study Information:
Thepurposeof the study is to test whether or not QPI-1002 could be used to lessen or prevent acute kidney injury after heart surgery. Another purpose is to better understand the safety of QPI-1002.
This study is closed
